Duration
24 months
Cost
Free to Patients
Phase
Phase IV
Closes
Aug 2025
Comparing standard 4-week vs extended 6-week natalizumab dosing intervals in RRMS patients.
Patient Advocacy Endorsed
This trial has been reviewed and endorsed by National MS Society. PAG endorsement means patient advocates have evaluated the trial design, risk-benefit profile, and patient-friendliness of this study.
Check your eligibility in under 2 minutes. No commitment required β a coordinator will guide you through next steps.
Check My Eligibility βFree to apply Β· No medical records needed to start
Trial Summary